Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need.


Midatech is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and ophthalmology. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

Midatech’s shares are traded on the Alternative Investment Market (AIM) of the London Stock Exchange under the ticker symbol MTPH (ISIN number GB00BRTL9B63).

Admission and First Day of Dealings on 8 December 2014

Major shareholders
http://www.midatechpharma.com/investors/share-information


http://www.midatechpharma.com/

Midas share tip Sunday 4 Jan 2014



Midatech Pharma floated on AIM only last month and specialises in nano-technology, using tiny particles of pure gold to treat cancer, diabetes and other medical conditions.


The shares are 264½p and should gain ground, as the board’s members are ambitious, experienced and have a history of success.

Midatech’s chief executive is Jim Phillips, a physician turned entrepreneur, with an accomplished track record, including Eusa Pharma, a private cancer specialist that was founded in 2006 and sold for $700million (£484million) just six years later.

The company is chaired by Rolf Stahel, who won widespread admiration as chief executive of FTSE 100 drugs group Shire from 1994 to 2002. Stahel went on to chair Eusa until it was sold. Now he and Phillips are determined to put their combined nous to work at Midatech.

The Oxford-based company has developed two innovative processes in the healthcare field. The first uses gold nano-particles to make cancer treatments work more effectively.

When the nano-particles are combined with existing drugs, chemotherapy becomes much more targeted, so it attacks the cancer and not the healthy tissue around it.


Not only does this mean fewer side-effects from treatment, it also enables patients to endure stronger dosages. Midatech is working principally on cancers that are extremely hard to treat, such as brain, liver and pancreatic tumours.

It is also working on a groundbreaking treatment for diabetes, using nano-particles to deliver insulin via a strip that can be popped inside the mouth. The strip dissolves within 30 seconds, a far more palatable and simpler solution than insulin injections.

When Midatech came to market last month, it acquired a business called Q Chip, which has developed a way to release drugs slowly into the body over days or weeks. This could have widespread uses for the ill, the elderly and people suffering from certain kinds of dementia.

Drug companies often take years to bring products to market because they have to jump through regulatory hoops. Midatech should be much more nimble because it is working with existing drugs but applying them in more effective ways. Phillips expects to bring his first product to market within 18 months and to introduce more treatments annually thereafter, both from the company’s current stable and from future acquisitions.

Midas verdict: Stahel and Phillips have been highly successful in healthcare and this latest venture has won the support of star investor Neil Woodford. His Woodford Fund Management firm owns 19.9 per cent of Midatech. Other investors would do well to follow suit.

Midatech Pharma PLC (AIM:MTPH) admitted to AIM. Read more at http://tinyurl.com/kq43z9m

Who Should Attend?Date:

Tuesday 24th February 2015

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:Sponsored by:

Positive Results in Proof-of-Concept Study
RNS
RNS Number : 2775F
Midatech Pharma PLC
19 February 2015

19 February 2015



Midatech Pharma PLC

("Midatech", the "Company" or the "Group")



Positive Results in Proof-of-Concept Study with Sustained Release Treatment for Uveitis



Sustained Release OpsiSporinas efficacious as orally administered Cyclosporin A at one thousandth of the dose



Midatech Pharma (AIM: MTPH), a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs, is pleased to announce positive results from a proof-of-concept in vivo study with OpsiSporin, a sustained release treatment for uveitis.



Uveitis is an inflammatory process affecting the iris, the ciliary body, the choroid layer or all or part of these structures of the eye. Whilst treatments exist, including corticosteroids and the immunosuppressant compound Cyclosporin A (CsA), a therapeutic that permanently controls inflammation, with a good short- and long-term safety profile, has yet to be developed.



OpsiSporin applies Midatech's Q Sphera® microencapsulation technology platform to precisely encapsulate CsA within polymer microspheres for sustained and extended release. The product has the potential to offer an effective alternative to steroids for the treatment of uveitis and a concomitant reduction in associated adverse effects such as cataracts and glaucoma.



The in vivo preclinical study sought to determine the efficacy of OpsiSporin microspheres following a single intravitreal injection, in the treatment of autoimmune uveitis, compared with oral administration of CsA, an intravitreal microsphere suspension vehicle and untreated controls. Intravitreal injection, a technique by which a drug is injected into the eye, has become a common method of treatment for many retinal diseases including AMD, Diabetic Retinopathy, and Retinal Vein Occlusions.



Results of the study showed a significant reduction in the severity of the disease when intravitreal injection with 4.5µg OpsiSporin was compared with microsphere suspension vehicle. The study also demonstrated a comparable reduction in severity when a single intravitreal injection of 4.5µg OpsiSporin was compared to the daily oral administration of 6.7 mg/kg/day CsA (a dose more than one thousand-fold greater). These results show the potential of OpsiSporin to offer patients with autoimmune uveitis a therapeutic alternative to steroids and CsA with high efficacy and reduced adverse effects.



Commenting on the results, Dr Jim Philips, CEO of Midatech Pharma, said: "The positive outcome of this proof-of-concept study is an important step forward in the development of a sustained release treatment for uveitis. The results showed OpsiSporin to be as efficacious as orally administered CsA at one thousandth of the dose, highlighting the significant value our microencapsulation technology can add to existing therapeutic molecules. We now look forward to progressing this product programme to the next stage with the aim of beginning clinical development as early as 2016."

Trading Update
RNS
RNS Number : 6533F
Midatech Pharma PLC
24 February 2015

24 February 2015



Midatech Pharma PLC

("Midatech", the "Company" or the "Group")



Trading Update



Midatech Pharma (AIM: MTPH), a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs, today announces a trading update ahead of its full year results for the twelve months ended 31 December 2014.



Midatech is pleased to report a successful year with full year revenue expected to be slightly ahead of company expectations and a strong net cash position at year end of approximately £30 million.



The Company intends to announce its preliminary full year 2014 results on 17 April 2015 and will hold an analyst presentation on the day.



Dr Jim Philips, CEO of Midatech Pharma, commented: "Last year was a hugely significant one for Midatech Pharma culminating in the company's IPO and the acquisition of Q-Chip in December. I am also pleased to report good revenue growth in the year driven by higher than expected partnership income. Our focus is now on executing the strategy we set out at the time of our IPO aimed at realising the huge potential of our two platform technologies to deliver a step change in the treatment of diabetes, cancers and ophthalmic diseases."

proactive investor -



Midatech Pharma aiming skyhigh with revolutionary targeted therapies

By Ian Lyall

March 03 2015, 11:18am
This highly targeted approach allows physicians to potentially administer lower doses and it also means there is little collateral damage.



Jim Phillips makes no apologies for his ambitions for Midatech Pharma (LON:MTPH), which listed on AIM late last year.

He wants it to be one of the few success stories of the life sciences industry, which has had more than its fair share of failures over the past three decades.

The US has successfully created some monsters of new wave medicines – the grande dames Amgen and Genzyme and more recently Biogen Idec, Gilead and Celgene.

While not strictly a biotechnology firm – as we’ll see later, it is at the forefront of nano-medicine – Midatech still wants to emulate the American model.

Phillips is not shy in revealing this means building a business valued at billions of pounds rather than hundreds of millions or tens of millions as it is today.

To help it do this it recruited an institutional shareholder base that understands and backs the Midatech model.

At the IPO last December, which raised £32mln of new money, it brought in the influential Neil Woodford, who used to run one of Britain’s largest funds for Invesco but is now going it alone.

He is joined on the investor register by well-known City names such as Legal & General and Octopus, as well as Finance Wales – in fact around 70% of the firm’s equity is in the hands of long-term holders.

Meanwhile, in chairman Rolf Stahel they have a man who helped create Shire, a multi-billion pound healthcare business and one of possibly two sector successes that have been incubated by the UK capital markets (the other being BTG).

Stahel and Phillips worked together on EUSA, a private cancer specialist they sold for around £480mln in 2012. The plan this time around is very definitely not to cash out.

So far, in putting part of the investment case we have ignored the unique technologies at the heart of Midatech, which unlike many of its peers on AIM is already revenue-generating.

Midatech is all about delivery. What do I mean by that? Well, its two platforms – carbohydrate-coated gold nanoparticle and its sustained release system – are about getting medicines to the right place in the right quantities at the right time.

The company’s gold nano-particles, or GNPs for short, promise a revolution in targeted therapies for cancer.

To radically simplify the process deployed (and being a non-scientist, I’m really simplifying it here) these GNPs act as guided missiles.

In treating cancer with traditional chemo-therapy, for instance, they are programmed to hit ONLY a specific tumour type with their payload.

This highly targeted approach allows physicians to potentially administer lower doses and it also means there is little collateral damage.

Its Q-Sphera technology works in a different way to deliver the drug at the right time.

It is a sustained release platform and has adopted 3D and ink jet printing techniques to create particles that dissolve in a “certain way over a certain time-scale”.

Midatech also has a joint-venture with Monosol Rx of the US to develop a strip that slowly dissolves in the mouth that rapidly delivers insulin.

Potentially more effective and faster acting than the other non-injected forms of the medication, it provides a painless, easy to use alternative to pumps and needles.

The growing obesity epidemic means the diabetes market is a huge one valued at an estimated US$40bn - and it is expanding rapidly.

The insulin product is also the most advanced in the portfolio as it enters phase-II clinical trials later this year.

Unlike the traditional biotech, the company has multiple shots on goal in cancer, ophthalmology and neuroscience as well as endocrinology.

Seven of the treatments in development are repurposing drugs already on the market, so could be fast-tracked through the regulatory process.

Meanwhile, the oncology portfolio is targeting areas of unmet medical needs such as brain tumours, liver and pancreatic cancer that have what’s called orphan status, which means the time to market may also be truncated.

Midatech also has revenue generating partnership agreements with five blue-chip and specialist pharma companies that mark it out from the norm on the junior market.

It plans to be profitable within “four to five years”, but could break-even earlier if it lands acquisitions that bring in additional income, or perhaps even their own sales teams.

“We have a vision and that is to be a sustainable leader,” said Phillips.

“One of my bugbears as a veteran of the industry is that Britain produces too few world-leading companies in our sector.

"We want to be recognised as one of the star companies coming out of the sector."

Research Collaboration Signed with Global Pharma
RNS
RNS Number : 7141G
Midatech Pharma PLC
06 March 2015

6 March 2015



Midatech Pharma PLC

("Midatech", the "Company" or the "Group")



Research Collaboration Signed with Global Pharmaceutical Company



Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical with a diversified portfolio of high-value assets, today announces the signature of a new research collaboration between MidaSol™ Therapeutics LP, a strategic joint venture between Midatech with MonoSol Rx LLC, and a major international pharmaceutical company (the "Partner").



Under the terms of the collaboration, MidaSol and the Partner will evaluate the preclinical effectiveness of MidaSol's gold-nanoparticle (GNP) and PharmaFilm® transbuccal (via the inside cheek) strip technologies for the needle-free delivery of an existing marketed diabetes drug for the Partner. The terms include an upfront payment, and several performance-driven milestones, details of which remain confidential. The project has a six-month term.



Commenting on the collaboration, Dr Jim Philips, CEO of Midatech Pharma, said: "This collaboration demonstrates the growing interest in the application of our GNP drug-conjugate technology with a range of therapeutic compounds for effective needle-free treatment. We aim to commercialise such products and ones in our own pipeline through partnerships and licensing opportunities and this agreement demonstrates the continuing successful implementation of our strategy."



Keith Kendall, CEO of MonoSol Rx, said: "The agreement we have signed with a major pharmaceutical company highlights the value of our joint venture with Midatech and the growing interest in needle-free products. We will now work alongside our new partner to progress this product through development with the goal of delivering it to diabetic patients around the world."

UPDATE - Midatech Pharma's collaboration agreement "provides significant risk mitigation"

By John Harrington

March 06 2015, 2:33pm
The broker speculates that the unnamed partner could be Lilly, AstraZeneca or Sanof


Nanomedicine specialist Midatech Pharma (LON:MTPH) is to work with a global pharmaceutical company on ways to deliver a diabetes treatment without recourse to injections.

The tie-up will be effected through MidaSol, a joint venture (JV) between Midatech and US firm MonoSol Rx. The JV is developing a strip that slowly dissolves in the mouth to rapidly deliver insulin.

Potentially more effective and faster acting than the other non-injected forms of the medication, it provides a painless, easy to use alternative to pumps and needles.

The unnamed major pharmaceuticals company already has a treatment for diabetes, but it is interested in learning whether MidaSol's gold-nanoparticle (GNP) and PharmaFilm oral strip technologies can effectively deliver the drug without users having to get the needle.

The terms of the collaboration agreement announced on Friday include an upfront payment, and several performance-driven milestones, details of which remain confidential. The project has a six-month term.

Speaking to Proactive Investors, Dr Jim Philips, chief executive officer (CEO) of Midatech, said it is the company's second agreement with a large pharmaceutical company in the diabetes area.

"This collaboration demonstrates the growing interest in the application of our GNP drug-conjugate technology with a range of therapeutic compounds for effective needle-free treatment," Dr Philips said in a stock market announcement.

"We aim to commercialise such products and ones in our own pipeline through partnerships and licensing opportunities and this agreement demonstrates the continuing successful implementation of our strategy" he added.

Keith Kendall, CEO of MonoSol Rx, said: "We will now work alongside our new partner to progress this product through development with the goal of delivering it to diabetic patients around the world."

Dr Philips told Proactive Investors that the most important thing for these types of collaborations is that they are validating Midatech's technologies.

"It's about proving they are commercially viable to partners, as well as our own internal programmes.

"Every time we add a revenue earning partnership it obviously helps us achieve our revenue growth projections and give us more potential upside in the future through licensing deals.

"The more products that use our technology at the end of the day, the more revenue we'll earn in the future," Dr Philips explained.

The growing obesity epidemic means the diabetes market is a huge one valued at an estimated US$40bn, and it is expanding rapidly.

The insulin product is the most advanced in the portfolio of Midatech, which floated at the end of 2014, and is set to enter phase-II clinical trials later this year.

Shares in Midatech were up 13.5p to 313.5p in mid-afternoon trading.

Panmure Gordon has initiated coverage of Midatech with a 420p price target, and described today's news as an exciting collaboration that significantly mitigates risk in the firm's entire diabetes franchise.

The broker speculates that the unnamed partner could be Lilly, AstraZeneca or Sanofi.

"At this stage, we view this collaboration as modest income generating whilst the pre-clinical feasibility is on-going," the broker said, as it stressed that treatment of diabetes represents just one strong on Midatech's bow.

"The main therapeutic focus includes diabetes, oncology, neurology and ophthalmologic conditions with a combined addressable market of more than US$90bn," the broker said. "The nano-pharmaceutical market itself is already worth some US$7bn+."

Panmure Gordon predicts the growth plans will receive a turbo boost from mergers & acquisitions activity.

"CEO Jim Phillips and chairman Rolf Stahel in particular have an excellent track record in pharmaceutical ‘buy and build’. Its relatively early-stage nature offers significant upside for investors.

"Capital raised should help with licensing deals, and also provide a realistic time frame for the company to become profitable and cash-generative. Phase IIa data from its insulin product is expected in H2 2015," noted analyst Savvas Neophytou.

Shares - Drug delivery specialist Midatech Pharma expects to report the first hard evidence its diabetes-controlling insulin strip works in the third quarter. This is just one of 12 products in the pipeline that focuses on the targeted delivery or controlled release of existing treatments. If regulators approve the strip in the coming years following the three-stage clinical trial process it could be the first non -injectable insulin treatment launched into what the company estimates is a $10 billion market.

Finals Friday 17 April

Midatech Pharma inks new deal with leading US cancer centre

By Ian Lyall

April 14 2015, 7:47am
There is a significant unmet medical need currently as glioblastoma is difficult to combat given the given the different cell types at play.
There is a significant unmet medical need currently as glioblastoma is difficult to combat given the given the different cell types at play.


Midatech Pharma (LON:MTPH) said it has inked a new collaboration with the America’s Dana-Farber Cancer Institute to test the pre-clinical effectiveness of its nano-medicines in the brain tumour glioblastoma.

The aim of the tie-up with this world leading research group, which is a teaching affiliate of the Harvard Medical School, is to find most effective targeted treatments as quickly as possible.

There is a significant unmet medical need currently as glioblastoma is difficult to combat given the given the different cell types at play.

Chief executive, Dr Jim Philips, said: "This collaboration demonstrates the growing interest in our technology across a range of therapeutic compounds and for specifically targeting certain types of cancer cells.

“Glioblastoma is a very common but hard to treat brain cancer condition with poor survival rates.

“Our goal is to develop an effective treatment that transforms patient outcomes via our collaboration with Dana-Farber."

Midatech has two platforms – a carbohydrate-coated gold nanoparticle and its sustained release system. Both are about getting medicines to the right place in the right quantities at the right time.

The company’s gold nano-particles, or GNPs for short, promise a revolution in targeted therapies for cancer.

To radically simplify the process deployed these GNPs act as guided missiles.

In treating cancer with traditional chemo-therapy, for instance, they are programmed to hit ONLY a specific tumour type with their payload.

This highly targeted approach allows physicians to potentially administer lower doses and it also means there is little collateral damage.

Its Q-Sphera technology works in a different way to deliver the drug at the right time.

It is a sustained release platform and has adopted 3D and ink jet printing techniques to create particles that dissolve in a certain way over a certain time-scale.

Preliminary Results
RNS
RNS Number : 5030K
Midatech Pharma PLC
17 April 2015

17 April 2015



Midatech Pharma PLC

("Midatech", the "Company" or the "Group")



Preliminary results for the year ending 31 December 2014



- Transformational year including IPO, acquisition of Q Chip, collaboration agreement and EU manufacturing grant



Midatech Pharma plc (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value assets, today announces its maiden audited preliminary results for the twelve month period ended 31 December 2014.



Operational Highlights (including post-period end)

· Awarded a €7.9m Horizon 2020 European Union grant (€3.4m direct to the Group) to fund manufacturing scale-up - September 2014

· Acquisition of Q Chip Limited ("Q Chip") bringing complementary technology and products, enabling sustained release over extended periods of time - December 2014

· Positive results achieved in proof-of-concept OpsiSporin study with sustained release treatment for uveitis (ocular inflammation) - February 2015

· Research collaboration agreement signed with unnamed global pharmaceutical company in field of diabetes - March 2015

· Appointment of Nick Robbins-Cherry, Finance Director in February 2014 and Dr Craig Cook, Chief Operating Officer in January 2014

· Research collaboration agreement signed with Dana-Farber Cancer Institute - April 2015



Financial Highlights

· Oversubscribed flotation on the AIM market of the London Stock Exchange in December 2014 raising £32.0m (before expenses)

· Combined proforma revenue ahead of expectations at £0.73m

· Strong balance sheet with £30.33m cash and deposits at 31 December 2014 (2013: £2.39m)

· Net loss after tax of £7.38m (2013: £4.08m) with net cash inflow in the year of £27.94m (2013: £2.25m)

· Tax credit receivable of £0.84m (2013: £0.80m)



Commenting on the maiden preliminary results, Dr Jim Philips, CEO of Midatech, said: "2014 was a transformational year for Midatech Pharma. Our goal is to build Midatech into a world-leading international specialty pharmaceutical company with a diversified portfolio of high-value assets and we are well on our path to achieving this.



"Our growth strategy is based on the maturation of our technology platforms, a clear focus on the key therapeutic areas within our pipeline and on the delivery of strategic later stage product focussed acquisitions.



"I would like to thank all of our staff and investors for their support and I look forward to leading Midatech through the next stages of its corporate development."

Proposed Acquisition of DARA BioSciences, Inc.

http://www.moneyam.com/action/news/showArticle?id=5050221

4 Jun Panmure Gordon 420.00 Buy

Initiation of Phase IIa study of insulin delivery
RNS
RNS Number : 8362T
Midatech Pharma PLC
23 July 2015

23 July 2015



Midatech Pharma PLC

("Midatech" or the "Company")



Initiation of Phase IIa study of insulin delivery via buccal strip for type 1 diabetes



Midatech (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value products in development, in partnership with MonoSol Rx, today announces that the first patient has been treated in a Phase IIa open label, cross-over, seven arm study of Insulin Buccal Soluble Film (MSL-001) for type 1 diabetes mellitus.



The objectives of the study are to establish the pharmacodynamic and pharmacokinetic profile, and safety and tolerability of MSL-001 (MidaForm® Insulin PharmFilm®) in comparison to subcutaneous administered human recombinant insulin (Humulin®).



The study is being conducted in Perth, Australia, with a total of 12 patients, male and female, aged 18 - 55 being treated from a screening pool of up to 35 subjects. The overall study duration is approximately five months.



MSL-001 contains recombinant human insulin which is non-covalently bound to glycan-coated gold nanoparticles and embedded in an oral, muco-adhesive, polymeric film for transbuccal delivery. The drug was invented by Midatech and MonoSol Rx and is being developed by the parties' joint venture, MidaSol Therapeutics.



Commenting on the study, Dr. Jim Philips, CEO of Midatech Pharma, said: "Diabetes incidence is forecast to hit 500m people, globally, by 2025; with our partnered transbuccal insulin strip, MSL-001 is targeting a $20 billion market, adding significant revenue potential to our growing portfolio of products."



- Ends -

Filing of Form F-4 Registration Statement with SEC
RNS
RNS Number : 7745V
Midatech Pharma PLC
12 August 2015

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION



12 August 2015



Midatech Pharma PLC

("Midatech" or the "Company")



Filing of Form F-4 Registration Statement with SEC





Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value products in development, today announced that it has filed with the United States Securities and Exchange Commission its Registration Statement on Form F-4 in connection with its previously announced offer for DARA BioSciences Inc.



Included within the Form F-4 are references to Midatech's Q1 2015 financial information, not previously disclosed, and an updated set of financial statements for the year ended 31 December 2014. Notes referenced therein detail that one of the intangible assets acquired with Midatech Pharma (Wales) Limited (formerly Q Chip Limited) has become impaired. This was as a result of further information of which the Board became aware subsequent to the approval of the 2014 statutory accounts, resulting in a £1.8m non-cash charge which will be restated in the opening balance sheet of the December 2015 statutory financial statements.



Included within the Midatech Group financial statements to 31 March 2015 are the following headlines:

· Revenue of £39,000

· Loss from operations of £2.674 million

· Total equity less liabilities of £39.298 million



This submission is subject to review and comment by the SEC, and may be revised further as necessary. The filed Form F-4 can be viewed on Midatech's website: www.midatechpharma.com/investors/reports-and-presentations



Commenting on the announcement, Dr. Jim Philips, CEO of Midatech Pharma, said: The submission of this filing demonstrates further positive progress towards the acquisition of DARA and, ultimately, brings Midatech closer towards developing our target therapeutic area of oncology as an international specialty pharma.



"It is also of note that the Q Chip acquisition is delivering significant product opportunities and value through the development of the Q Octreo and OpsiSporin programmes."



- Ends -

12 Aug Panmure Gordon 420.00 Buy

Ocular Agreement with Ophthotech
RNS
RNS Number : 9024V
Midatech Pharma PLC
13 August 2015

13 August 2015



Midatech Pharma PLC

("Midatech" or the "Company")



Ocular Agreement with Ophthotech



- Development of sustained delivery formulations for rapidly growing ophthalmology market

- Underpins Midatech's financial guidance for 2015



Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value products in development, today announced an agreement with Ophthotech Corporation (NASDAQ: OPHT), a biopharmaceutical company specialising in the development of novel therapeutics to treat back of the eye diseases, to explore the feasibility of using Midatech's Q Sphera microencapsulation technology for sustained delivery formulations of select Ophthotech products for the treatment of wet Age-related Macular Degeneration and other ocular indications.



While the financial terms of the agreement are not disclosed ‎the Directors believe that the agreement underpins a significant amount of the market forecasts of revenue for 2015.



Commenting on the collaboration, Dr. Jim Philips, CEO of Midatech Pharma, said: "Drug delivery technology partnering is one of our three core strategies and this agreement with Ophthotech is a perfect fit for Midatech. Using our unique R&D and production facilities in Wales and Spain we will continue, in line with strategy, to generate early revenues to help drive the Group towards financial self-sustainability."



- Ends -

Half Yearly Report
RNS
RNS Number : 8973Y
Midatech Pharma PLC
14 September 2015

14 September 2015



Midatech Pharma PLC

("Midatech" or the "Company")



Interim results for the six months ended 30 June 2015





Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value products in development, today announces its interim results for the six months ended 30 June 2015.



Operational Highlights

· Offer, negotiation and agreement to acquire DARA Biosciences Inc. in the US

· Positive results in a proof-of-concept in vivo study for our OpsiSporin sustained release treatment for uveitis

· Approval and site initiation of our Phase IIa transbuccal Insulin (MidaFormTM) clinical trial

· Commissioning of new laboratories and offices at our Head Office site in Abingdon

· Three new collaborations signed

· Commencement of product candidate testing in vivo for glioblastoma



Financial Highlights

· Revenue grew from £36k in the six months to June 2014 to £324k (up 800%)

· Administrative expenses increased from £1,862k in the six months to June 2014 to £3,768k (up 102%)

· Research and development costs increased from £1,260k in the six months to June 2014 to £1,822k (up 45%)

· Net cash outflow from operating activities (before changes in working capital) was £4,983k, up 70% from £2,923k in the six months to June 2014. The cash balance at 30 June 2015 stood at £24.34m.

· Loss per share decreased by 54% from 39p in the six months to June 2014 to 18p



Commenting on the interim results, Dr. Jim Philips, CEO of Midatech Pharma, said: "2015 has shown a strong start to Midatech's next stage of corporate development. With the proposed acquisition of DARA BioSciences, three new collaborations and further progress with our own pipeline, we continue to build upon our strategy with the aim of creating a world-class specialty pharmaceutical company."



Conference call today

Dr Jim Phillips, Chief Executive Officer and Nick Robbins-Cherry, Finance Director, will host a conference call for analysts at 1300 BST today. The conference call ID is: 24926910.

UK: +44 1452 555 566

USA: +1 631 510 7498



A replay of the call will be available for 30 days after the event, using the same conference ID: 24926910.

UK: +44 1452 550 000

USA: +1 866 247 4222



- Ends

Who Should Attend?Date:

Thursday 19th November 2015

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:Sponsored by: